Frontlight ResearchEarly access
Haemophilia trials in Norway
1 of 5 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleThis is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
- Where
- Oslo
- Age
- 18 years to 64 years
- People
- 4 worldwide
- Run by
- Cell4Cure AB
See details and how to join2022-502030-12-01